Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

3.974 -0.017 (-0.41%)
Streaming Delayed Price Updated: 3:53 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,588
Open 4.100
Bid (Size) 3.750 (1)
Ask (Size) 4.900 (1)
Prev. Close 3.990
Today's Range 3.750 - 4.100
52wk Range 3.685 - 5.670
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
-14.55%
-14.55%
1 Month
-4.25%
-4.25%
3 Month
-16.14%
-16.14%
6 Month
-13.05%
-13.05%
1 Year
-13.05%
-13.05%

More News

Read More
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Via News Direct
Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients
Via Benzinga
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Via TheNewswire.com
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Via Benzinga
Coya Therapeutics: This BioPharma Company Has Some Big News To Share
Via Benzinga
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Via TheNewswire.com
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Via News Direct
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via TheNewswire.com
Topics Death
Exposures Death
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via News Direct
Topics Death
Exposures Death
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Via Benzinga
Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
Via Benzinga
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
Via TheNewswire.com
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.